ClinicalTrials.gg
RecruitingNCT07673107Updated Oct 27, 2026

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor

A Phase 2 interventional study of AGN-151607-DP and Placebo for AGN-151607-DP in Upper Limb Essential Tremor, sponsored by AbbVie. Recruiting at 21 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 27, 2026First site in CanadaStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 146 studies in Essential Tremor with a site in United States — 40 open to participants now, 46 under way, 1 of them phase 3. Essential Tremor · United States.

Planned enrollment
22nd of 104
94 · median 30
Started
2026
with 8 others
Phase 2
21 of 146
1 open now
Primary completion
2028-11
later than 30 of 44 live
Registered
143rd of 146
by date

Among the 146 studies in Essential Tremor with a site in United States, this one is the 22nd largest by planned enrollment of the 104 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 in phase 2, reaches primary completion later than 30 of the 44 other live ones, and was the 143rd registered.

Essential Tremor

272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.

Browse Essential Tremor studies →

Open to participants now

40 of the 146 studies in Essential Tremor with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Essential Tremor with a site in United States, or all of them as a file.
02

Study summary

Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET.

AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada.

Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks.

The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.

03

Conditions studied

  • Upper Limb Essential Tremor

Browse trials for

Keywords

  • Upper Limb Essential Tremor
  • AGN-151607-DP
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum body weight of 50 kg (110 pounds) at Screening.
  • Diagnosis of essential tremor (ET) in accordance with the modified Tremor Research Investigation Group (TRIG) criteria, as follows:

    • Bilateral postural tremor with or without kinetic tremor, involving hands and forearms
    • Tremor of other body parts may or may not be present in addition to upper limb (UL) tremor
    • Bilateral tremor may or may not be asymmetric
    • Tremor that is reported by the participant to be persistent, although the amplitude may fluctuate.

Exclusion criteria

Exclusion Criteria:

  • History of any medical condition that may put the participant at increased risk with exposure to purified botulinum toxin type A complex, including diagnosed muscular dystrophy (e.g., Duchenne's muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or any other significant disease that might interfere with neuromuscular junctional disorders.
  • History of an allergic reaction to or significant sensitivity to AGN-151607-DP or its and/or other botulinum toxins.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    AGN-151607-DP

    Participants will receive AGN-151607-DP.

    Drug: AGN-151607-DP

  • Placebo comparator
    Placebo for AGN-151607-DP

    Participants will receive Placebo for AGN-151607-DP.

    Drug: Placebo for AGN-151607-DP

Interventions

  • Intramuscular Injection

  • DrugPlacebo for AGN-151607-DP

    Intramuscular Injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS)

    TETRAS assesses participants' ability to function. Items are rated on a 5-category response scale from 0 (no tremor) to 4 (severe tremor).

    Time frame: 72 weeks

  2. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: 72 weeks

Secondary outcomes

  1. Change From Baseline in The Essential Tremor Rating Assessment Scale - Upper Limb (TETRAS-UL)

    TETRAS Upper Limb (UL) Scale is an item of the TETRAS performance subscale that is designed to assess upper limb tremor. Items are scored from 0 to 4, with 0 indicating no tremor and 4 indicating a severe tremor.

    Time frame: 72 weeks

  2. Change From Baseline in Clinical Global Impression of Severity (CGIS)

    CGI-S is a single item used to measure the clinician's impression of the current severity of the patient's essential tremor. The measure uses a 5-point rating scale with scores ranging none to very severe.

    Time frame: 72 weeks

07

Study locations

21 of 21 sites recruiting
  • The Neurology Center of Southern California - Carlsbad /ID# 278194
    Carlsbad, California 92011, United States
    Recruiting
  • Neuro Pain Research Center /ID# 277899
    Fresno, California 93710, United States
    Recruiting
  • Neurology Center Of North Orange County /ID# 278490
    Fullerton, California 92835, United States
    Recruiting
  • New England Institute for Clinical Research /ID# 277315
    Stamford, Connecticut 06905, United States
    Recruiting
  • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277079
    Boca Raton, Florida 33486, United States
    Recruiting
  • Charter Research - Winter Park /ID# 277875
    Orlando, Florida 32803-1839, United States
    Recruiting
  • Emerald Coast Neurology /ID# 277898
    Pensacola, Florida 32504-8649, United States
    Recruiting
  • Kansas Institute of Research /ID# 277068
    Overland Park, Kansas 66211-1358, United States
    Recruiting
  • Dent Neurologic Institute - Amherst /ID# 277242
    Amherst, New York 14226, United States
    Recruiting
  • True North Neurology /ID# 278118
    Commack, New York 11725, United States
    Recruiting
  • Neurology - Triad /ID# 277088
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Mount Carmel Health System /ID# 278234
    New Albany, Ohio 43054, United States
    Recruiting
  • Veracity Neuroscience /ID# 277081
    Memphis, Tennessee 38157, United States
    Recruiting
  • Texas Neurology /ID# 277067
    Dallas, Texas 75206-5202, United States
    Recruiting
  • Lone Star Neurology /ID# 278266
    Frisco, Texas 75035, United States
    Recruiting
  • Houston Methodist Hospital /ID# 277326
    Houston, Texas 77030, United States
    Recruiting
  • University of Virginia /ID# 278191
    Charlottesville, Virginia 22908, United States
    Recruiting
  • Inland Northwest Research /ID# 277077
    Spokane, Washington 99202, United States
    Recruiting
  • Center For Neurological Disorders /ID# 277048
    Greenfield, Wisconsin 53228, United States
    Recruiting
  • Centre de Recherche St-Louis /ID# 277106
    Lévis, Quebec G6W 0M5, Canada
    Recruiting
  • Genge Partners /ID# 277096
    Pointe-Claire, Quebec H9R 4Y2, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2028, 29 months after the start.

Of 20 phase 2 interventional studies under Essential Tremor, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 29, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added — first site in Canada
Show 18 added (16 United States, 2 Canada)
  • The Neurology Center of Southern California - Carlsbad /ID# 278194 · Carlsbad, United States
  • Neurology Center Of North Orange County /ID# 278490 · Fullerton, United States
  • New England Institute for Clinical Research /ID# 277315 · Stamford, United States
  • Emerald Coast Neurology /ID# 277898 · Pensacola, United States
  • Kansas Institute of Research /ID# 277068 · Overland Park, United States
  • Dent Neurologic Institute - Amherst /ID# 277242 · Amherst, United States
  • True North Neurology /ID# 278118 · Commack, United States
  • Neurology - Triad /ID# 277088 · Winston-Salem, United States
  • Veracity Neuroscience /ID# 277081 · Memphis, United States
  • Texas Neurology /ID# 277067 · Dallas, United States
  • Lone Star Neurology /ID# 278266 · Frisco, United States
  • Houston Methodist Hospital /ID# 277326 · Houston, United States
  • University of Virginia /ID# 278191 · Charlottesville, United States
  • Inland Northwest Research /ID# 277077 · Spokane, United States
  • Center For Neurological Disorders /ID# 277048 · Greenfield, United States
  • Centre de Recherche St-Louis /ID# 277106 · Lévis, Canada
  • Genge Partners /ID# 277096 · Pointe-Claire, Canada
  • Mount Carmel Health System /ID# 278234 · New Albany, United States
across 2 updates, Oct 22, 2026 – Oct 27, 2026
Start date
Jun 18, 2026→Jun 23, 2026
Oct 22, 2026
Show all 2 updates
  1. Oct 27, 2026
    1 site added
    Show site
    • Mount Carmel Health System /ID# 278234 · New Albany, United States
  2. Oct 22, 2026
    17 sites added — first site in Canada
    Show 17 added (15 United States, 2 Canada)
    • The Neurology Center of Southern California - Carlsbad /ID# 278194 · Carlsbad, United States
    • Neurology Center Of North Orange County /ID# 278490 · Fullerton, United States
    • New England Institute for Clinical Research /ID# 277315 · Stamford, United States
    • Emerald Coast Neurology /ID# 277898 · Pensacola, United States
    • Kansas Institute of Research /ID# 277068 · Overland Park, United States
    • Dent Neurologic Institute - Amherst /ID# 277242 · Amherst, United States
    • True North Neurology /ID# 278118 · Commack, United States
    • Neurology - Triad /ID# 277088 · Winston-Salem, United States
    • Veracity Neuroscience /ID# 277081 · Memphis, United States
    • Texas Neurology /ID# 277067 · Dallas, United States
    • Lone Star Neurology /ID# 278266 · Frisco, United States
    • Houston Methodist Hospital /ID# 277326 · Houston, United States
    • University of Virginia /ID# 278191 · Charlottesville, United States
    • Inland Northwest Research /ID# 277077 · Spokane, United States
    • Center For Neurological Disorders /ID# 277048 · Greenfield, United States
    • Centre de Recherche St-Louis /ID# 277106 · Lévis, Canada
    • Genge Partners /ID# 277096 · Pointe-Claire, Canada
    Start date Jun 18, 2026→Jun 23, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07673107
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jun 23, 2026
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion